Skip to content

Study of antineoplastic drugs induced early cardiotoxicity in patients with Lymphoma

Study of antineoplastic drugs induced early cardiotoxicity in patients with Lymphoma

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100054721
Enrollment
Unknown
Registered
2021-12-25
Start date
2020-09-01
Completion date
Unknown
Last updated
2022-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lymphoma

Interventions

case series:No

Sponsors

the First Affiliated Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Aged over 18 years; 2. Patients who are clinically diagnosed with lymphoma, have treatment indications after evaluation by a hematologist, and receive chemotherapy; 3. Those who obtained informed consent after having a detailed understanding of the purpose and protocol of this study.

Exclusion criteria

Exclusion criteria: 1. Those with a history of chemotherapy; 2. Those who have chemotherapy contraindications such as significant liver and kidney function damage after evaluation by a hematologist, and the above contraindications cannot be eliminated after active treatment and can tolerate chemotherapy; 3. There are contraindications to the special imaging examination used in this study, including internal metal implants, claustrophobic patients, pregnant women, allergic to drugs used in the examination process, contrast agents, and others who are not suitable for cardiac color Doppler ultrasound; 4. Known heart disease in the past, including myocarditis, various types of cardiomyopathy, coronary heart disease, high heart disease, severe valvular heart disease, significant arrhythmia, with or without heart failure, etc.; 5. Pregnant women; 6. Glaucoma patients; 7. Other researchers think that it is not suitable to participate in this researcher.

Design outcomes

Primary

MeasureTime frame
creatine kinase isoenzyme;Troponin;high-sensitivity c-reactive protein;N-terminal precursor brain linatide;tumor suppressor factor 2;Overall longitudinal strain;left ventricular ejection fraction;

Countries

China

Contacts

Public ContactTang Xiaoqiong

the First Affiliated Hospital of Chongqing Medical University

tlscqmu@126.com+86 13638332366

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 13, 2026